Published online Sep 15, 2023. doi: 10.4239/wjd.v14.i9.1385
Peer-review started: May 4, 2023
First decision: May 15, 2023
Revised: May 25, 2023
Accepted: August 7, 2023
Article in press: August 7, 2023
Published online: September 15, 2023
Diabetic nephropathy (DN) is one of the common complications of diabetes, mainly manifested as glomerular damage. As it progresses, DN may lead to chronic renal failure (CRF), which seriously affects quality of life and life expectancy.
Hemodialysis filtration is an effective method for treating CRF, but patients receiving hemodialysis often experience abnormalities in blood calcium and phosphorus. Paroxycarbinol can promote intestinal calcium absorption and inhibit the secretion and differentiation of Paricalcitol cells by binding to vitamin D receptors. However, it is still unclear whether periostenol has an effect on calcium phosphate metabolism disorder in patients with CRF due to DN.
Supplement the blank of paracalcitol combined with hemodiafiltration in the treatment of CRF, and increases the clinical treatment plan for disorder of calcium and phosphate metabolism during hemodialysis and filtration.
We retrospectively analyzed and observed the effect of paricalcitol combined with hemodiafiltration on calcium phosphate metabolism disorder in patients with CRF due to DN. For the first time, a risk model for predicting efficacy was established using a least absolute shrinkage and selection operator (LASSO) regression model.
We found that the combination of paricalcitol and hemodialysis filtration significantly improved the metabolic disorder of calcium phosphate metabolism disorder in patients, and improved efficacy. Using the LASSO model, we established a risk score to predict efficacy, which provides a new reference for clinical treatment and efficacy prediction.
Paricalcitol can improve calcium phosphate metabolism disorder in hemodialysis patients, and the risk model established by LASSO regression model effectively predicts clinical efficacy.
As a retrospective study, we cannot collect more samples and observe the prognosis of patients. We hope to conduct randomized controlled trials in future studies to observe the long-term prognosis.